胃肠道癌化疗进展PPT.ppt

胃肠道癌化疗进展; 胃 癌;背 景;胃癌化疗作用; 胃癌单药疗效;Cumulative results of neoadjuvant chemotherapy for locally advanced gastric cancer (11 phase II series).;Neo-adjuvant treatment for laparoscopy staged locally advanced gastric cancer(T3-4):EORTC 40954.;Neo-adjuvant chemotherapy : FAMTX + surgery vs surgery in operable gastric cancer (POCOM).;Results of POCOM (1).;Results of POCOM (2).;Neo-adjuvant chemotherapy (MAGIC trial).;Results of MAGIC Trial( ASCO 2003);Neo-adjuvant vs postoperativechemotherapy (SWS-SAKK 43/99).;术中化疗;术后化疗;姑息性化疗;Randomized trials of chemotherapy vs best supportive care in advanced gastric cancer.;胃癌常用的化疗方案;胃癌常用的化疗方案;胃癌常用的化疗方案卜;EORTC 40902.;FAMTX vs ECF (n=274).;High-dose 5-FU in advanced gastric cancer.;Design of EORTC study in advanced gastric cancer (40953); randomized phase II design;Results of EORTC study in advanced gastric cancer (40953).;New drugs in advanced gastric cancer;New-generation regimens in gastric cancer.;Phase II data with new drugs.;Phase III trials with new drugs.;The future: patient/tumor adapted therapies.;有可能与化疗联合治疗胃癌新作用机制的药物;总 结;总 结; 大 肠 癌;背 景;诊断时分期;转移性大肠癌的化疗;转移性大肠癌的化疗;转移性大肠癌化疗的选择;5-Fu bolus vs 5-FU CI (meta-analysis);5-FU alone vs 5-FY+CF(meta analysis);CPT-11 single in 1stLine CRC;CPT-11,5-FU,CF联合1线治疗ACRC;5-FU,CPT-11,L-OHP三种有效药物使用比率越高MST越长;大肠癌预后因素;CRC远处转移部位及发生率;III期大肠癌的辅助治疗;III期大肠癌的辅助治疗(n=929);III期大肠癌的辅助治疗(n=915);III期大肠癌的辅助治疗(n=3759);III期大肠癌的辅助治疗(n=4947);IIIII期大肠癌的辅助化疗(n=3351);大肠癌肝转移灶切除后的生存预后因素;不能切除的肝转移;靶向生物治疗;Xeloda对照5FU/CF(Mayo-clinic);UFT/CF vs 5FU/CF (Mayo-Clinic);;CPT-11联合L-OHP;Bevacizumab (Avastin);Cetuximab (IMC-225);CRC的生物化疗;;Thank You